In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The effect of heart rate on brachial and central blood pressure in longterm beta-blocker therapy

Session Poster Session 4

Speaker Martin Serg

Congress : ESC Congress 2018

  • Topic : hypertension
  • Sub-topic : Hypertension: Pharmacotherapy
  • Session type : Poster Session
  • FP Number : P3807

Authors : M Serg (Tartu,EE), T Teeaar (Tartu,EE), J Eha (Tartu,EE), M Zilmer (Tartu,EE), J Kals (Tartu,EE), P Kampus (Tartu,EE)

Authors:
M. Serg1 , T. Teeaar1 , J. Eha1 , M. Zilmer2 , J. Kals2 , P. Kampus1 , 1University of Tartu, Department of Cardiology, Institute of Clinical Medicine - Tartu - Estonia , 2University of Tartu, Department of Biochemistry, Institute of Biomedicine and Translational Medicine - Tartu - Estonia ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 808

Background: Increased resting heart rate (HR) contributes to higher cardiovascular risk. We have previously shown that a conventional beta-blocker (BB) metoprolol and a vasodilating BB nebivolol equally reduce brachial blood pressure (BP) and HR, only nebivolol reduces central (aortic) BP. However, recent short-term studies have proposed that baseline HR values as well as change in HR with BB may augment central BP. Therefore, the use of BBs as antihypertensive drugs remains controversial.

Purpose: We aimed to study whether baseline HR level determines the change in brachial and central BP in long-term BB therapy in hypertensive patients.

Methods: We conducted a randomized, double-blind study in 80 hypertensive patients, who received either nebivolol 5 mg or metoprolol succinate 50–100 mg daily for one year. We performed brachial and central BP measurements at baseline and at the end of the study. The patients in each treatment arm were then divided into subgroups by their baseline HR (<65 bpm and ≥65 bpm).

Results: After 1 year of treatment brachial BP was reduced in all subgroups. In patients with baseline HR <65 bpm there was no change in HR and central BP in the metoprolol group, whereas in these patients nebivolol significantly reduced HR and central systolic BP (130±15 vs. 120±14 mmHg; p<0.01) and pulse pressure (49±10 vs. 43±8 mmHg; p=0.01). In patients with baseline HR ≥65 bpm both, metoprolol and nebivolol reduced HR significantly, but there was a significant reduction in central systolic BP (136±17 vs. 125±11 mmHg; p<0.05) only in the nebivolol group.

Conclusion: Our study suggests that despite HR and brachial BP reduction with BBs there is no additional augmentation of central BP. Vasodilating BB nebivolol reduces brachial and central BP regardless of baseline HR level.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are